Epigenetic alterations play a central role in the initiation and progression of cancer by influencing gene expression without altering the underlying DNA sequence. Targeting epigenetic regulators has emerged as a promising strategy for cancer therapy. This project focuses on the therapeutic potential of Protein Arginine Methyltransferase (PRMT) inhibitors and other epigenetic modifiers in treating hematological and solid cancers. We will explore the mechanisms underlying epigenetic dysregulation in these malignancies, evaluate the efficacy of PRMT inhibitors, and assess their synergistic effects with combined epigenetic therapies. The ultimate goal is to provide a comprehensive understanding of how targeting epigenetic pathways can lead to improved cancer treatments.
Mokslinis vadovas / Supervisor: Dr. Veronika Borutinskaitė
Kontaktai / Contacts:
tel. / phone: +37062190948
Programme: Biochemistry N 004